Eagle Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Eagle Pharmaceuticals, Inc.‘s stocks are currently a part of 133 hedge funds’ portfolios, which represents 78.54% of the total amount of its stocks outstanding. This makes up a total of 10.08M shares of Eagle Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -13.15% or -1.52M shares fewer. As for the holding position changes, 41.35% (55) of current hedge fund investors increased the number of shares held, 34.59% (46) of current holders sold a part of the shares held, and 20.3% (27) closed the holdings completely. 16 hedge funds are new holders of Eagle Pharmaceuticals, Inc. stock in Q3 2022, it is 12.03% of total holders.
Hedge funds holding Eagle Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 164 |
|---|---|
| Q1 2018 | 170 |
| Q2 2018 | 181 |
| Q3 2018 | 184 |
| Q4 2018 | 179 |
| Q1 2019 | 179 |
| Q2 2019 | 177 |
| Q3 2019 | 180 |
| Q4 2019 | 173 |
| Q1 2020 | 165 |
| Q2 2020 | 161 |
| Q3 2020 | 167 |
| Q4 2020 | 162 |
| Q1 2021 | 153 |
| Q2 2021 | 143 |
| Q3 2021 | 150 |
| Q4 2021 | 161 |
| Q1 2022 | 158 |
| Q2 2022 | 160 |
| Q3 2022 | 133 |
Hedge funds changes in Eagle Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 28 | 53 | 57 | 27 | -1 |
|---|---|---|---|---|---|
| Q1 2018 | 24 | 55 | 61 | 17 | 13 |
| Q2 2018 | 32 | 56 | 60 | 20 | 13 |
| Q3 2018 | 28 | 81 | 42 | 22 | 11 |
| Q4 2018 | 26 | 72 | 54 | 32 | -5 |
| Q1 2019 | 20 | 55 | 61 | 20 | 23 |
| Q2 2019 | 19 | 67 | 55 | 18 | 18 |
| Q3 2019 | 17 | 57 | 73 | 14 | 19 |
| Q4 2019 | 16 | 55 | 73 | 17 | 12 |
| Q1 2020 | 18 | 58 | 61 | 23 | 5 |
| Q2 2020 | 17 | 55 | 68 | 21 | 0 |
| Q3 2020 | 25 | 65 | 54 | 18 | 5 |
| Q4 2020 | 15 | 50 | 70 | 20 | 7 |
| Q1 2021 | 13 | 64 | 55 | 18 | 3 |
| Q2 2021 | 11 | 56 | 52 | 21 | 3 |
| Q3 2021 | 16 | 42 | 62 | 8 | 22 |
| Q4 2021 | 22 | 47 | 66 | 11 | 15 |
| Q1 2022 | 15 | 54 | 65 | 18 | 6 |
| Q2 2022 | 17 | 50 | 72 | 10 | 11 |
| Q3 2022 | 16 | 55 | 46 | 27 | -11 |
Hedge funds changes in Eagle Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 5,679,000 | 5,513,000 |
|---|---|---|
| Q1 2018 | 7,071,000 | 6,344,000 |
| Q2 2018 | 14,753,000 | 14,406,000 |
| Q3 2018 | 18,672,000 | 16,251,000 |
| Q4 2018 | 3,183,000 | 6,124,000 |
| Q1 2019 | 4,735,000 | 8,997,000 |
| Q2 2019 | 7,985,000 | 10,606,000 |
| Q3 2019 | 4,235,000 | 1,991,000 |
| Q4 2019 | 15,444,000 | 5,040,000 |
| Q1 2020 | 795,000 | 3,593,000 |
| Q2 2020 | 983,000 | 388,000 |
| Q3 2020 | 1,345,000 | 16,000 |
| Q4 2020 | 0 | 0 |
| Q1 2021 | 0 | 0 |
| Q2 2021 | 0 | 0 |
| Q3 2021 | 1,634,000 | 0 |
| Q4 2021 | 693,000 | 0 |
| Q1 2022 | 24,000 | 485,000 |
| Q2 2022 | 0 | 0 |
| Q3 2022 | 3,597,000 | 0 |